Bristol-Myers Squibb and Syngene International extend research collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) and Syngene International, India's largest contract research organization, have announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.
AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014
- Details
- Category: AstraZeneca
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors on 2 June 2014, as compelling data from over 40 scientific abstracts related to AstraZeneca and MedImmune investigational medicines were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Bayer and Orion Corporation to develop and commercialize novel prostate cancer treatment
- Details
- Category: Bayer
Bayer has entered into a global agreement with Orion Corporation, a pharmaceutical company based in Espoo, Finland, (Nasdaq OMX Helsinki: ORNAV and ORNBV) for the development and commercialization of the compound ODM-201, an investigational novel oral androgen receptor inhibitor. ODM-201 is in clinical development for the treatment of patients with prostate cancer.
Pfizer and the Avon Foundation for Women announce $1 million grants program
- Details
- Category: Pfizer
Despite the high level of public attention devoted to breast cancer awareness, more than 60 percent of respondents in a new national survey commissioned by Pfizer Inc. say they know little to nothing about metastatic breast cancer.(1) The survey is the first of its kind to examine the general public's understanding of metastatic breast cancer, which affects up to 250,000 women and men in the U.S. today.(2)
Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS
- Details
- Category: Novartis
In support of World MS Day, Novartis announced today the launch of the 7-Day Challenge to Live Like You for people with MS. The 7-Day Challenge to Live Like You, one of the first integrations of emerging technological trends by a pharmaceutical company, is simple: using wearable technology or accessing personal online systems that people use on a daily basis, including calendars, social media channels and fitness trackers, people with MS are invited to track their activities for seven days and gain valuable insights into what works best for their lifestyle.
Pfizer brings frequent heartburn relief OTC with new Nexium® 24HR
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has announced the introduction in the U.S. of over-the-counter (OTC) Nexium®24HR, making The Purple Pill® available for the treatment of frequent heartburn (two or more days a week) in adults (18 years and older). Heartburn affects more than 60 million men and women in the United States at least once a month with 15 million Americans suffering from it daily.(1)
Clarification regarding Pfizer statement
- Details
- Category: AstraZeneca
AstraZeneca PLC ("AstraZeneca") notes the announcement made by Pfizer Inc. ("Pfizer") dated 19 May 2014 seeking to clarify certain matters set out in its announcement on 18 May 2014 which set out its final proposal to AstraZeneca (the "Final Proposal Announcement"). Following some questions from shareholders, AstraZeneca wishes to make clear the following points:
More Pharma News ...
- AstraZeneca rejects final proposal from Pfizer
- Abbott enhances its position in fast-growing Latin American market
- MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial
- Boehringer Ingelheim will make detailed clinical trial data available to the scientific community
- Bayer HealthCare extends access to clinical trial data
- Pfizer announcement and AstraZeneca statement
- More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day